On March 3rd, 2021, the Food and Drug Administration (FDA) approved Lobrena (lorlatinib) for the first line treatment of non-small cell lung cancer (NSCLC) which has spread outside of the lungs that has a change in ALK identified by an FDA approved test. The FDA based their approval on the results of a clinical trial which found that patients receiving Lobrena went longer before experiencing progression than those who received Xalkori (crizotinib).
The FDA’s updated approval of Lobrena gives people with lung cancer a new choice for first-line treatment.
Subscribe to The Magnifying LeNS: Learning New Science Quarterly to stay up to date
on the latest in lung cancer research and treatment.
Leave A Comment